Adagrasib在ESMO会议引发关注
I/II期KRYSTAL-1试验显示,KRASG12C抑制剂adagrasib单药或联合EGFR抑制剂西妥昔单抗对转移性结直肠癌均显示鼓舞人心的临床活性。单药组疾病控制率87%,无进展生存期5.6个月;联合组疾病控制率100%,无进展生存期数据尚未成熟。该结果与sotorasib数据在2021年欧洲肿瘤内科学会大会上公布。
要点
- adagrasib单药治疗转移性结直肠癌疾病控制率87%,PFS 5.6个月。
- adagrasib联合西妥昔单抗疾病控制率达100%,PFS数据未成熟。
- KRASG12C抑制剂在结直肠癌中显示临床活性,联合EGFR抑制值得进一步研究。
核心结论
- adagrasib单药或联合西妥昔单抗对转移性结直肠癌均显示鼓舞人心的临床活性。
研究设计与样本
- I/II期KRYSTAL-1试验,评估adagrasib单药及联合西妥昔单抗治疗转移性结直肠癌。
主要发现
- adagrasib单药组疾病控制率为87%,无进展生存期为5.6个月。
- adagrasib联合西妥昔单抗组疾病控制率为100%,无进展生存期数据尚未成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In phase I/II KRYSTAL-1 trial, the KRASG12C inhibitor adagrasib demonstrated encouraging clinical activity against metastatic colorectal cancer, both as a monotherapy and when combined with the EGFR inhibitor cetuximab. In patients who received adagrasib alone, the disease control rate was 87% and progression-free survival was 5.6 months. Among patients who received the drug combination, the disease control rate was 100%; data on progression-free survival were immature. The findings, along with data on the KRASG12C inhibitor sotorasib, were presented at the 2021 European Society for Medical Oncology Congress.
引用
- Adagrasib Data Create Buzz at ESMO. Cancer Discov. 2021. PMID: 34607832. doi:10.1158/2159-8290.CD-NB2021-0385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。